Loading…
Rhythm Pharmaceuticals, Inc. is projected to rise to $102.26 by 2027, a +12% move from its current price of $91.42. RYTM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $89.09 | $91.43 | $93.83 | +0.01% |
| May 30 | $88.15 | $91.44 | $94.86 | +0.02% |
| May 31 | $87.44 | $91.45 | $95.66 | +0.04% |
| Jun 1 | $86.84 | $91.46 | $96.33 | +0.05% |
| Jun 2 | $86.32 | $91.47 | $96.94 | +0.06% |
| Jun 3 | $85.85 | $91.49 | $97.49 | +0.07% |
| Jun 4 | $85.43 | $91.50 | $98.00 | +0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $85.43 | $91.50 | $98.00 | +0.08% |
| Week 2 | $83.10 | $91.57 | $100.91 | +0.17% |
| Week 3 | $81.38 | $91.65 | $103.22 | +0.25% |
| Week 4 | $79.96 | $91.73 | $105.22 | +0.34% |
| Week 5 | $78.74 | $91.80 | $107.03 | +0.42% |
| Week 6 | $77.66 | $91.88 | $108.70 | +0.50% |
| Week 7 | $76.69 | $91.96 | $110.27 | +0.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rhythm Pharmaceuticals, Inc., is a commercial-stage biopharmaceutical company focused on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor agonist for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trials for the treatment of Prader-Willi syndrome and MC4R deficiency.
The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist in phase 2 for MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist in phase 1 for hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc.
in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Rhythm Pharmaceuticals, Inc. trades under the symbol RYTM and has a current price of $87.84 with a market capitalization of $6.02B, ranking 1213 by market cap. The stock sits in a context of a neutral near-term technical posture, with a 30-day trading range from $73.52 to $104.94 and a current RSI of 50.
The company’s near-term technicals show the 50-day simple moving average at $87.07 and the 200-day moving average at $98.66, with key support at $81.36 and resistance at $96.61. These factors frame a price environment that may drift within a defined interval while longer-term forecasts imply meaningful upside potential.
A major floor 18.5% below — a decisive break under it would weaken the trend.
The nearest floor, 11.0% below — buyers have tended to step in here.
The nearest ceiling, 5.7% above — a clean break opens room to run.
A major ceiling 19.2% above — clearing it would confirm fresh momentum.
Key RYTM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RYTM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $89.98 | Buy | $90.07 | Buy |
| MA 10 | $90.18 | Buy | $89.94 | Buy |
| MA 20 | $89.54 | Buy | $89.46 | Buy |
| MA 50 | $87.13 | Buy | $89.68 | Buy |
| MA 100 | $93.64 | Sell | $92.08 | Sell |
| MA 200 | $98.65 | Sell | $91.04 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.94 | Neutral |
| Stoch RSI (14) | 36.09 | Neutral |
| CCI (20) | 34.76 | Neutral |
| Williams %R (14) | -51.22 | Info |
| MACD (12,26,9) | -0.09 | Sell |
| ROC (12) | -2.92 | Sell |
| Bollinger %B (20,2) | 0.61 | Neutral |
| Stochastic %K (14) | 48.78 | Neutral |
| TRIX (15) | 0.15 | Buy |
| Awesome (5,34) | 1.80 | Buy |
| Ultimate (7,14,28) | 49.99 | Neutral |
| Momentum (10) | 0.11 | Buy |
| Aroon Osc (25) | 16.00 | Buy |
| Hull MA (9) | 89.84 | Buy |
| ADX (14) | 10.71 | Neutral |
| ATR (14) | 2.16 | Info |
The 30-day technical picture is neutral, with the RSI at 50 and the price near the 50-day moving average of $87.07. The 200-day moving average sits higher at $98.66, suggesting the longer-term trend remains uncertain near term. The 30-day range spans from $73.52 to $104.94, indicating a broad trading band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $75.82 | $91.42 | $120.59 | 0% | Neutral | |
| $81.50 | $102.26 | $135.70 | +12% | Neutral | |
| $81.28 | $104.63 | $143.66 | +14% | Neutral | |
| $94.46 | $124.24 | $175.27 | +36% | Bullish | |
| $106.27 | $142.45 | $205.61 | +56% | Bullish | |
| $117.70 | $160.53 | $236.41 | +76% | Bullish | |
| $135.06 | $187.20 | $280.71 | +105% | Bullish | |
| $133.58 | $187.98 | $286.55 | +106% | Bullish | |
| $133.36 | $190.39 | $294.64 | +108% | Bullish | |
| $144.53 | $209.20 | $328.34 | +129% | Bullish | |
| $206.38 | $317.98 | $529.46 | +248% | Bullish | |
| $397.13 | $680.97 | $1,236.36 | +645% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $75.82 | $91.42 | $107.67 | +0.00% |
| June 2026 | $78.90 | $92.56 | $111.09 | +1.25% |
| July 2026 | $78.16 | $92.42 | $112.36 | -0.15% |
| August 2026 | $80.13 | $95.35 | $117.06 | +3.17% |
| September 2026 | $81.40 | $97.35 | $120.48 | +2.10% |
| October 2026 | $79.33 | $95.34 | $118.85 | -2.07% |
| November 2026 | $78.03 | $94.17 | $118.14 | -1.22% |
| December 2026 | $78.86 | $95.55 | $120.59 | +1.46% |
Click any year to see its month-by-month RYTM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The RYTM price prediction for 2026 points to an average of $91.42 (low $75.82, high $120.59) — a potential gain of 0% on today's $91.42. A consolidation phase looks the most probable path here.
In 2027, RYTM is projected to trade between $81.50 and $135.70, averaging $102.26 — a potential gain of +12% from today's $91.42. That is up +12% on the projected 2026 average. Price action looks broadly range-bound.
Rhythm Pharmaceuticals, Inc.'s 2028 outlook centres on $104.63, within a $81.28 to $143.66 range. That is up +2% on the projected 2027 average. That marks a +14% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, RYTM could reach as high as $175.27, with a base case around $124.24 and support toward $94.46 — roughly +36% from $91.42. Momentum favours further upside here.
Expect RYTM to range from $106.27 to $205.61 through 2030. The $142.45 average target implies a +56% move from current prices. That is up +15% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The RYTM price prediction for 2031 points to an average of $160.53 (low $117.70, high $236.41) — a potential gain of +76% on today's $91.42. Momentum favours further upside here.
In 2032, RYTM is projected to trade between $135.06 and $280.71, averaging $187.20 — a potential gain of +105% from today's $91.42. That is up +17% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Rhythm Pharmaceuticals, Inc.'s 2033 outlook centres on $187.98, within a $133.58 to $286.55 range. That is up 0% on the projected 2032 average. That marks a +106% change versus current levels. Momentum favours further upside here.
By 2034, RYTM could reach as high as $294.64, with a base case around $190.39 and support toward $133.36 — roughly +108% from $91.42. Buyers look set to stay in control over this stretch.
Expect RYTM to range from $144.53 to $328.34 through 2035. The $209.20 average target implies a +129% move from current prices. That is up +10% on the projected 2034 average. Momentum favours further upside here.
The RYTM price prediction for 2040 points to an average of $317.98 (low $206.38, high $529.46) — a potential gain of +248% on today's $91.42. Buyers look set to stay in control over this stretch.
In 2050, RYTM is projected to trade between $397.13 and $1,236.36, averaging $680.97 — a potential gain of +645% from today's $91.42. That is up +114% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in RYTM today (≈ 10.938525 RYTM) could be worth
$7,448.78
+$6,448.78 (+645%) by 2050 · US Dollar
Based on the average projected RYTM price of $680.97 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RYTMwould be worth at today's price.
$1,000 invested in RYTM on May 27, 2025 (≈ 16.8976 RYTM) would be worth
$1,544.78
+$544.78 (+54.5%) today · 1.54× · US Dollar
Based on a RYTM entry price of $59.18 vs. today's $91.42.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $90.64 | $1,008.61 | +0.9% |
| 1 month ago | $85.2 | $1,073 | +7.3% |
| 3 months ago | $98.07 | $932.19 | -6.8% |
| 6 months ago | $109.09 | $838.02 | -16.2% |
| 1 year ago | $59.18 | $1,544.78 | +54.5% |
| All time (5.0y) ago | $19.53 | $4,681 | +368.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RYTM forecast.
Our base-case forecast reaches $180.00 around 2032.
Implied market cap at $180.00: $12.34B
The multi-year forecast shows a path of rising averages and higher upside potential by mid-century. In 2026 the avg is $87.84 with a min of $75.82 and a max of $115.66; by 2027 the avg is $96.15 (min $76.31, max $128.31) with ROI 9.4; by 2028 the avg is $97.82 (min $75.59, max $135.22) with ROI 11.4; 2029 shows an avg of $114.82 (min $86.76, max $163.20) with ROI 30.7. The forecast for 2030 gives an avg of $129.61 (min $96.02, max $188.63) with ROI 47.6, continuing with 2031 avg $146.81 (min $106.80, max $218.13) ROI 67.1; 2032 shows avg $171.12 (min $122.40, max $259.02) ROI 94.8; 2033 avg $168.98 (min $118.96, max $260.13) ROI 92.4; 2034 avg $170.52 (min $118.24, max $266.63) ROI 94.1; 2035 avg $187.10 (min $127.88, max $296.82) ROI 113.
By 2040 the avg is $280.93 (min $179.79, max $473.58) ROI 219.8, and by 2050 the avg reaches $590.79 (min $337.62, max $1,088.44) ROI 572.6. These figures carry inherent uncertainty and are not guaranteed, reflecting potential upside in a bullish trajectory while acknowledging market and regulatory risks.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $129.61 with ROI 47.6, with a min of $96.02 and a max of $188.63.
Forecasts indicate potential upside across 2027–2050, with the average price rising to $129.61 by 2030 and $590.79 by 2050, but these are estimates and not guarantees; risk and market conditions apply.
Yes. The 2033 max forecast is $260.13, with the 2033 avg at $168.98 and a min of $118.96.
Current price: $87.84. Market cap: $6.02B. The stock is ranked 1213 by market capitalization.
The 2040 forecast shows an avg of $280.93 with ROI 219.8 (min $179.79, max $473.58).
Rhythm Pharmaceuticals, Inc. Community Discussion
0Share your Rhythm Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.